On Friday, Humacyte Inc (NASDAQ: HUMA) opened higher 0.40% from the last session, before settling in for the closing price of $2.47. Price fluctuations for HUMA have ranged from $1.15 to $8.24 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 42.43% over the past five years. Company’s average yearly earnings per share was noted 79.88% at the time writing. With a float of $125.44 million, this company’s outstanding shares have now reached $155.12 million.
Let’s look at the performance matrix of the company that is accounted for 220 employees. In terms of profitability, gross margin is 23.12%, operating margin of -1433.23%, and the pretax margin is -1002.79%.
Humacyte Inc (HUMA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Humacyte Inc is 19.13%, while institutional ownership is 40.58%. The most recent insider transaction that took place on Apr 14 ’25, was worth 9,999. In this transaction Chief Commercial Officer of this company bought 6,493 shares at a rate of $1.54, taking the stock ownership to the 22,018 shares. Before that another transaction happened on Apr 10 ’25, when Company’s CFO and Chief Corp. Deve. Off. bought 20,000 for $1.53, making the entire transaction worth $30,600. This insider now owns 40,600 shares in total.
Humacyte Inc (HUMA) Latest Financial update
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.48 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.24) by -0.24. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 79.88% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Check out the current performance indicators for Humacyte Inc (HUMA). In the past quarter, the stock posted a quick ratio of 3.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 739.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.69, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.25 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Humacyte Inc (NASDAQ: HUMA) saw its 5-day average volume 5.05 million, a positive change from its year-to-date volume of 3.8 million. As of the previous 9 days, the stock’s Stochastic %D was 44.15%.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 60.18%, which indicates a significant increase from 48.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.21 in the past 14 days, which was higher than the 0.20 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.41, while its 200-day Moving Average is $3.26.
